Search

everythinglearnresearchcommunity

for

Search:↓

Certain nutraceuticals may enhance hair growth without affecting the cancer-fighting properties of tamoxifen.

The conclusion is that managing hair loss conditions like FFA and melanoma requires individualized approaches, considering new findings and balancing treatment benefits with potential risks.

Men are increasingly interested in cosmetic treatments that enhance masculinity and address aging without downtime, with tailored approaches for different ethnicities and a focus on hair restoration and body contouring.

5-ARI therapy may help prevent prostate cancer progression.

Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.

Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.

Both vaginal testosterone cream and Estring effectively manage vaginal dryness in women with early-stage breast cancer on aromatase inhibitors.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.

ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.

Most adverse reactions to the treatment were mild, with nausea being the most common.

5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.

A six-drug treatment for metastatic breast cancer showed promising results with low side effects, especially in premenopausal women.

5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.

A male with aromatase deficiency improved bone health with estradiol treatment.

Including androgens in hormone therapy may lower breast cancer risk.

Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.